Disease area
Hematologic malignancies
Multiple myeloma
B-cell malignancies
Myeloid malignancies
Classical hematology
Showing 4 recruiting clinical trials
Recurrent or metastatic head and neck squamous cell carcinoma
OrigAMI-4
Phase
b
NCT06385080
Compound
Amivantamab (EGFR × MET bispecific Ab) ± SOC
Recurrent or metastatic head and neck squamous cell carcinoma
OrigAMI-5
Phase
NCT07276399
Compound
Amivantamab (EGFR × MET bispecific Ab) + pembrolizumab + carboplatin
Treatment-naive, platinum-ineligible locally advanced head and neck squamous cell carcinoma
NANORAY-312
Phase
NCT04892173
Compound
JNJ-90301900 (NBTXR3) + RT ± cetuximab
Locally advanced head and neck squamous cell carcinoma
LUMIRAY
Phase
NCT07219212
Compound
JNJ-90301900 (NBTXR3) + cisplatin + IMRT
The safety and efficacy of the investigational use of these products have not been determined.
There is no guarantee that the investigational uses listed will be filed with and/or approved for marketing by any regulatory agency.
Ab, antibody; EGFR, epidermal growth factor receptor; IMRT, intensity modulated radiation therapy; MET, mesenchymal epithelial transition factor; RT, radiation therapy; SOC, standard of care.